Content
All Posts > Content under Healthcare
Teva Surprised On The Upside Today; Reporting Q4 Sales Of $6.5 Billion
Article By:
Vivian Lewis
Read
Monday, February 13, 2017 3:31 PM EDT
Teva, today reported Q4 sales of $6.5 bn and full year sales of $21.9 bn, both nicely over estimates, thanks to its continued good performance in its two main business lines, generics and multiple sclerosis drug Copaxone.
In this article: TEVA
RedHill Expects Bekinda Top-Line Data In Q2
Article By:
Jason Napodano
Read
Monday, February 13, 2017 2:05 PM EDT
RedHill Biopharma Ltd. announced that the final patient has been enrolled in the company's Phase 3 clinical study examining Bekinda as a treatment for acute gastroenteritis and gastritis.
In this article: RDHL
Allergan Plc. Announces Intention To Acquire Zeltiq Aesthetics
Article By:
Lorimer Wilson
Read
Monday, February 13, 2017 12:12 PM EDT
Pharma giant Allergan plc. is adding another line of cosmetic treatments to its portfolio, announcing today that it will acquire body contouring specialist ZELTIQ Aesthetics for nearly $2.5 billion in cash.
Israeli Pharmaceuticals Giant Teva Pharmaceutical Industries Ltd. Q4 Earnings Beat Street
Article By:
Lorimer Wilson
Read
Monday, February 13, 2017 9:32 AM EDT
Israeli pharmaceuticals giant Teva Pharmaceutical Industries Ltd. posted better than expected fourth quarter earnings results on Monday and reiterated its strong outlook, sending its shares higher in morning trading.
In this article: TEVA
Recent Stock Purchase February 2017
Article By:
Keith Park
Read
Sunday, February 12, 2017 11:44 PM EDT
I started the month looking at my usual consumer oriented stocks as many have been trading at much better levels in recent weeks when compared to just last summer.
Large Cap Biopharmaceuticals: Update On Financial Metrics
Article By:
Rod Raynovich
Read
Sunday, February 12, 2017 4:12 AM EDT
We have updated the comparison of eight large cap biopharma stocks post 2016 earnings for the period ending 2/10/17. Keep in mind that in January 2016 there was a severe correction with stocks dropping 25-30% with lows being hit in February 2016.
Immunovaccine: Biotech Stock With Very Strong Bullish Momentum
Article By:
Taki Tsaklanos
Read
Sunday, February 12, 2017 2:25 AM EDT
Immunovaccine's volume is currently very high compared to previous levels, so it will be crucial to see how much additional buying interest the company will get from other market participants.
In this article: IMMVF
Moving Targets: Investors Need To Discriminate!
Article By:
Gary Tanashian
Read
Friday, February 10, 2017 3:04 PM EDT
2017 is a year that investors will need to discriminate, first and foremost against their own internal bias and secondarily against a market that is grinding out discrete directions week by week.
Biotech ETFs Powered By Q4 Earnings
Article By:
Sweta Killa
Read
Friday, February 10, 2017 12:08 PM EDT
Improved earnings are driving the biotech space and ETFs higher over the past 10 days. Investors could closely monitor the movement in the products and could tap the potential surge through ETFs.
Health Insurance Industry Outlook - February 2017
Article By:
Zacks Investment Research
Read
Friday, February 10, 2017 5:32 AM EDT
The healthcare space as a whole has been in the eye of a storm over the past year, with the divergent policy platforms of the two presidential campaigns offering different paths for the sector going forward.